PMID- 31218784
OWN - NLM
STAT- MEDLINE
DCOM- 20190813
LR  - 20210109
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 110
IP  - 8
DP  - 2019 Aug
TI  - Immunohistochemistry for identification of CCND1, NSD2, and MAF gene 
      rearrangements in plasma cell myeloma.
PG  - 2600-2606
LID - 10.1111/cas.14109 [doi]
AB  - The t(11;14)/CCND1-IGH, t(4;14)/NSD2(MMSET)-IGH, and t(14;16)/IGH-MAF gene 
      rearrangements detected by fluorescence in situ hybridization (FISH) are used for 
      risk stratification in patients with multiple myeloma (MM). Compared with 
      conventional FISH techniques using fresh cells, immunohistochemistry (IHC) is 
      much more cost- and time-efficient, and can be readily applied to routinely 
      prepared formalin-fixed, paraffin-embedded (FFPE) materials. In this study, we 
      performed tissue FISH and IHC employing FFPE specimens, and examined the 
      usefulness of IHC as a tool for detecting CCND1, NSD2, and MAF gene 
      rearrangements. CD138 signals were used to identify plasma cells in tissue FISH 
      and IHC analyses. With cohort 1 (n = 70), we performed tissue FISH and 
      subsequently IHC, and determined IHC cut-off points. In this cohort, the 
      sensitivity and specificity for the 3 molecules were >/=.90 and >/=.96, respectively. 
      With cohort 2, using MM cases with an unknown gene status (n = 120), we performed 
      IHC, and the gene status was estimated using the cut-off points determined with 
      cohort 1. The subsequent FISH analysis showed that the sensitivity and 
      specificity for the 3 molecules were >/=.92 and >/=.98, respectively. CCND1, NSD2, 
      and MAF gene rearrangements were estimated accurately by IHC, suggesting that 
      conventional FISH assays can be replaced by IHC.
CI  - (c) 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Murase, Takayuki
AU  - Murase T
AD  - Department of Pathology and Molecular Diagnostics, Nagoya City University 
      Graduate School of Medical Sciences, Nagoya, Japan.
FAU - Ri, Masaki
AU  - Ri M
AUID- ORCID: 0000-0002-9617-486X
AD  - Department of Hematology and Oncology, Nagoya City University Graduate School of 
      Medical Sciences, Nagoya, Japan.
FAU - Narita, Tomoko
AU  - Narita T
AD  - Department of Hematology and Oncology, Nagoya City University Graduate School of 
      Medical Sciences, Nagoya, Japan.
FAU - Fujii, Keiichiro
AU  - Fujii K
AD  - Department of Pathology and Molecular Diagnostics, Nagoya City University 
      Graduate School of Medical Sciences, Nagoya, Japan.
FAU - Masaki, Ayako
AU  - Masaki A
AD  - Department of Pathology and Molecular Diagnostics, Nagoya City University 
      Graduate School of Medical Sciences, Nagoya, Japan.
FAU - Iida, Shinsuke
AU  - Iida S
AUID- ORCID: 0000-0002-4951-960X
AD  - Department of Hematology and Oncology, Nagoya City University Graduate School of 
      Medical Sciences, Nagoya, Japan.
FAU - Inagaki, Hiroshi
AU  - Inagaki H
AUID- ORCID: 0000-0001-6157-636X
AD  - Department of Pathology and Molecular Diagnostics, Nagoya City University 
      Graduate School of Medical Sciences, Nagoya, Japan.
LA  - eng
GR  - 26-A-4/National Cancer Center Research and Development Fund/
GR  - 15K08351/Ministry of Education, Culture, Sports, Science, and Technology/
GR  - 16K07179/Ministry of Education, Culture, Sports, Science, and Technology/
GR  - 16K09855/Ministry of Education, Culture, Sports, Science, and Technology/
GR  - 15ck0106077h0002/Japan Agency for Medical Research and Development/
PT  - Journal Article
DEP - 20190711
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (CCND1 protein, human)
RN  - 0 (MAF protein, human)
RN  - 0 (Proto-Oncogene Proteins c-maf)
RN  - 0 (Repressor Proteins)
RN  - 136601-57-5 (Cyclin D1)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
RN  - EC 2.1.1.43 (NSD2 protein, human)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Cyclin D1/*genetics
MH  - Female
MH  - Gene Rearrangement/*genetics
MH  - Histone-Lysine N-Methyltransferase/*genetics
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*genetics
MH  - Proto-Oncogene Proteins c-maf/*genetics
MH  - Repressor Proteins/*genetics
MH  - Sensitivity and Specificity
PMC - PMC6676137
OTO - NOTNLM
OT  - FFPE tissue sections
OT  - gene rearrangements
OT  - immunohistochemistry
OT  - multiple myeloma
OT  - tissue fluorescence in situ hybridization
EDAT- 2019/06/21 06:00
MHDA- 2019/08/14 06:00
PMCR- 2019/08/01
CRDT- 2019/06/21 06:00
PHST- 2019/02/06 00:00 [received]
PHST- 2019/06/01 00:00 [revised]
PHST- 2019/06/17 00:00 [accepted]
PHST- 2019/06/21 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2019/06/21 06:00 [entrez]
PHST- 2019/08/01 00:00 [pmc-release]
AID - CAS14109 [pii]
AID - 10.1111/cas.14109 [doi]
PST - ppublish
SO  - Cancer Sci. 2019 Aug;110(8):2600-2606. doi: 10.1111/cas.14109. Epub 2019 Jul 11.